Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa.
|Articles|June 14, 2022
The Mainstream Patient: June 14
Author(s)Linda Stocum, Associate Editor
This week's edition of the Mainstream Patients features stories about skin care for trans women, Aztec clay for the skin, and more.
Advertisement
In this week’s edition, Self dives into ticks and InStyle talks varicose veins. Cosmopolitan reviews Aztec clay for the skin and Glamour talks transgender skin care. Elle explains personalized birth control and Allure discusses undereye circles.
Here’s How to Tell If a Tick Head Is Still in Your Skin, According to Doctors
4 Easy Ways to Treat Varicose Veins, According to Experts
Aztec Clay Mask Review: We Tested the Viral Face Mask on Every Skin Type
For Transgender Women, Beauty Products Go Far Beyond the Surface
Personalized Birth Control Is Finally Available
Here's How to Get Rid of Undereye Bags and Dark Circles to Look More Refreshed
Advertisement
Related to this article
According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
2
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
3
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
4
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
5